Citations

Clear

2303 citation(s) found for "Yu, Edward".

Recurrence patterns among patients with sinonasal mucosal melanoma: A multi‐institutional study
Pandrangi, Vivek C. , Mace, Jess C. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H. , Fung, Nicholas , Hong, Michelle , Johnson, Brian J. , Kohanski, Michael A. , Lee, Jivianne T. , Nabavizadeh, Seyed Ali , Obermeyer, Isaac P. , Adappa, Nithin D. , Smith, Timothy L. , Suh, Jeffrey D. , Wang, Marilene B. , Beswick, Daniel , Johnson, Brian Jake , Kshirsagar, Rijul S , Kuan, Edward C , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Abiri, Arash , Adappa, Nithin D. , Eide, Jacob G. , Fung, Nicholas, Kshirsagar, Rijul S. , Le, Christopher H. , Pinheiro‐Neto, Carlos , Choby, Garret , Geltzeiler, Mathew

Mayo Clinic

International Forum of Allergy & Rhinology | June 2, 2023 | Volume: 13 | Issue: 12 | Pages: 2156-2164

10.1002/alr.23204 | PMID 37265013 Get It

AbstractObjectiveTo evaluate recurrence patterns and survival after recurrence among patients with sinonasal mucosal melanoma (SNMM).MethodsThis was a multi‐institutional retrospective review from seven U.S. institutions of patients with SNMM from 1991 to 2022. Recurrence was categorized as local, regional, distant, or multifocal. Kaplan‐Meier tests were used to evaluate disease‐free survival (DFS), overall survival (OS), and post‐recurrence survival (PRS) reported with standard errors (SE) and log‐rank testing used for comparison. Cox‐regression was further used, with hazard ratios (HR) and 95% confidence intervals (CI) reported.ResultsAmong 196 patients with SNMM, there were 146 patients with recurrence (74.5%). Among all patients, 60‐month DFS (SE) was 15.5% (2.9%), 60‐month OS (SE) was 44.7% (3.7%), mean age ± standard deviation at diagnosis was 69.7 ± 12.5 years, and 54.6% were female. In 26 patients who underwent primary treatment of the neck, 60‐month DFS did not differ from no treatment (p > 0.05). Isolated distant recurrence was most common (42.8%), followed by local (28.3%), multifocal (20.7%), and regional recurrence (8.3%). Among patients with regional recurrence in the neck, there was no 60‐month PRS benefit for patients undergoing salvage neck dissection or radiation (p > 0.05). Among patients with distant recurrence, only immunotherapy was associated with improved 12‐month PRS (HR = 0.32, 95% CI = 0.11–0.92, p = 0.034), and no treatment group was associated with improved 24‐ or 60‐month PRS (p > 0.05).ConclusionSNMM is associated with a high recurrence rate and poor survival. Primary treatment of the neck was not associated with reduced recurrence, and immunotherapy for treatment of distant recurrence was associated with increased 12‐month PRS.
Incorporation of a biparietal narrowing metric to improve the ability of machine learning models to detect sagittal craniosynostosis with 2D photographs
Anderson, Megan, Jungbauer, Dana , Ahn, Edward S. , Stoltz, Petronella, Martin, Jonathan E. , Hersh, David S. , Anderson, Megan G., Leclair, Nathan K. , Bookland, Markus J.

Mayo Clinic

Neurosurgical Focus | June 1, 2023 | Volume: 54 | Issue: 6 | Pages: E9

10.3171/2023.3.focus2349 | PMID 37283444 Get It

OBJECTIVE Sagittal craniosynostosis is the most common form of craniosynostosis and typically results in scaphocephaly, which is characterized by biparietal narrowing, compensatory frontal bossing, and an occipital prominence. The cephalic index (CI) is a simple metric for quantifying the degree of cranial narrowing and is often used to diagnose sagittal craniosynostosis. However, patients with variant forms of sagittal craniosynostosis may present with a "normal" CI, depending on the part of the suture that is closed. As machine learning (ML) algorithms are developed to assist in the diagnosis of cranial deformities, metrics that reflect the other phenotypic features of sagittal craniosynostosis are needed. In this study the authors sought to describe the posterior arc angle (PAA), a measurement of biparietal narrowing that is obtained with 2D photographs, and elucidate the role of PAA as an adjuvant to the CI in characterizing scaphocephaly and the potential relevance of PAA in new ML model development. METHODS The authors retrospectively reviewed 1013 craniofacial patients treated during the period from 2006 to 2021. Orthogonal top-down photographs were used to calculate the CI and PAA. Distribution densities, receiver operating characteristic (ROC) curves, and chi-square analyses were used to describe the relative predictive utility of each method for sagittal craniosynostosis. RESULTS In total, 1001 patients underwent paired CI and PAA measurements and a clinical head shape diagnosis (sagittal craniosynostosis, n = 122; other cranial deformity, n = 565; normocephalic, n = 314). The area under the ROC curve (AUC) for the CI was 98.5% (95% confidence interval 97.8%–99.2%, p < 0.001), with an optimum specificity of 92.6% and sensitivity of 93.4%. The PAA had an AUC of 97.4% (95% confidence interval 96.0%–98.8%, p < 0.001) with an optimum specificity of 94.9% and sensitivity of 90.2%. In 6 of 122 (4.9%) cases of sagittal craniosynostosis, the PAA was abnormal while the CI was normal. This means that adding a PAA cutoff branch to a partition model increases the detection of sagittal craniosynostosis. CONCLUSIONS Both CI and PAA are excellent discriminators for sagittal craniosynostosis. Using an accuracy-optimized partition model, the addition of the PAA to the CI increased model sensitivity compared to using the CI alone. Using a model that incorporates both CI and PAA could assist in the early identification and treatment of sagittal craniosynostosis via automated and semiautomated algorithms that utilize tree-based ML models.
Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
Hammers, Dustin B. , Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Gao, Sujuan , Kirby, Kala, Aisen, Paul , Dage, Jeffrey L. , Foroud, Tatiana M., Griffin, Percy , Grinberg, Lea T. , Kramer, Joel H. , Kukull, Walter A. , Mundada, Nidhi S. , Joie, Renaud La , Soleimani‐Meigooni, David N. , Polsinelli, Angelina J. , Rumbaugh, Malia, Touroutoglou, Alexandra , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Beckett, Laurel , Jack, Clifford R. , Koeppe, Robert A. , Iaccarino, Leonardo , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Womack, Kyle , Musiek, Erik , Salloway, Steve , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | May 31, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13160 | PMID 37256497 Get It

AbstractObjectiveThe Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early‐onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data‐collection mid‐point.MethodsData from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid‐positive EOAD [n = 212], and amyloid‐negative early‐onset non‐Alzheimer's disease [EOnonAD; n = 70]).ResultsCognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.ConclusionsWe present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant.HIGHLIGHTS Findings represent the most comprehensive baseline characterization of sporadic early‐onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.
Classification and Management of Disorders of the J Pouch
Santiago, Priscila , Raffals, Laura E. , Barnes, Edward L.

Mayo Clinic

American Journal of Gastroenterology | May 30, 2023 | Volume: 118 | Issue: 11 | Pages: 1931-1939

10.14309/ajg.0000000000002348 | PMID 37252759 Get It

Total abdominal proctocolectomy with ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC) is associated with substantial complications despite the benefits of managing refractory and/or neoplasia-associated disease. For the purpose of this review, we focused on the diagnosis of some of the most common inflammatory and structural pouch disorders and their respective management. Pouchitis is the most common complication, and it is typically responsive to antibiotics. However, chronic antibiotic refractory pouchitis (CARP) has been increasingly recognized, and biologic therapies have emerged as the mainstay of therapy. Crohn's-like disease of the pouch (CLDP) can affect up to 10% of patients with UC after IPAA. Medical options are similar to CARP therapies, including biologics with immunomodulators. Studies have shown higher efficacy rates of biologics for CLDP when compared with those for CARP. In addition, managing stricturing and fistulizing CLDP is challenging and often requires interventional endoscopy (balloon dilation and/or stricturotomy) and/or surgery. The implementation of standardized diagnostic criteria for inflammatory pouch disorders will help in advancing future therapeutic options. Structural pouch disorders are commonly related to surgical complications after IPAA. We focused on the diagnosis and management of anastomotic leaks, strictures, and floppy pouch complex. Anastomotic leaks and anastomotic strictures occur in approximately 15% and 11% of patients with UC after IPAA, respectively. Further complications from pouch leaks include the development of sinuses, fistulas, and pouch sepsis requiring excision. Novel endoscopic interventions and less invasive surgical procedures have emerged as options for the management of these disorders.
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk
Aglago, Elom K. , Kim, Andre E. , Lin, Yi , Qu, Conghui , Evangelou, Marina , Yu, Ren , Morrison, John L. , Albanes, Demetrius , Arndt, Volker , Barry, Elizabeth L. , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Díez‐Obrero, Virginia , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jordahl, Kristina M. , Joshi, Amit D. , Kundaje, Anshul , Li, Li , Mandic, Marko , Obón‐Santacana, Mireia , Nan, Hongmei , Nassir, Rami , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Prentice, Ross L. , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Gauderman, W. James , Peters, Ulrike , Kim, Andre E , Ren, Yu , Morrison, John L , Bien, Stephanie A , Bishop, D Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D , Budiarto, Arif , Carreras-Torres, Robert , Casey, Graham , Cenggoro, Tjeng Wawan , Chan, Andrew T , Chang-Claude, Jenny , Chen, Xuechen , Conti, David V , Devall, Matthew A M , Diez-Obrero, Virginia , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Gallinger, Steven , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Hidaka, Akihisa , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Joshi, Amit D , Kawaguchi, Eric , Keku, Temitope O , Kundaje, Anshul , Larsson, Susanna C , Marchand, Loïc Le , Lewinger, Juan Pablo , Li, Li , Lynch, Brigid M , Mahesworo, Bharuno , Mandic, Marko , Obón-Santacana, Mireia , Moreno, Victor , Murphy, Neil , Nan, Hongmei , Nassir, Rami , Newcomb, Polly A. , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Papadimitriou, Nikos , Pardamean, Bens , Peoples, Anita R , Platz, Elizabeth A. , Potter, John D , Prentice, Ross L , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Scacheri, Peter C , Schmit, Stephanie L , Schoen, Robert E , Shcherbina, Anna , Slattery, Martha L , Stern, Mariana Carla , Su, Yu-Ru , Tangen, Catherine M , Thibodeau, Stephen N , Thomas, Duncan C , Tian, Yu , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Vodicka, Pavel , Wang, Jun , White, Emily , Wolk, Alicja , Woods, Michael O , Wu, Anna H. , Zemlianskaia, Natalia , Hsu, Li , Gauderman, W James , Peters, Ulrike , Tsilidis, Konstantinos K , Campbell, Peter T , Arndt, Volker , Aglago, Elom K , Albanes, Demetrius , Qu, Conghui , Bien, Stephanie A. , Buchanan, Daniel D. , Carreras‐Torres, Robert , Chan, Andrew T. , Conti, David V. , Dimou, Niki , Drew, David A. , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Murphy, Neil , Palmer, Julie R. , Pardamean, Bens , Potter, John D. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Shcherbina, Anna , Tangen, Catherine M. , Tian, Yu , Ulrich, Cornelia M. , Wolk, Alicja , Tsilidis, Konstantinos K. , Campbell, Peter T.

Mayo Clinic

Cancer Research | May 30, 2023 | Volume: 83 | Issue: 15 | Pages: 2572-2583

10.1158/0008-5472.can-22-3713 | PMID 37249599 Get It

Abstract Colorectal cancer risk can be impacted by genetic, environmental, and lifestyle factors, including diet and obesity. Gene-environment interactions (G × E) can provide biological insights into the effects of obesity on colorectal cancer risk. Here, we assessed potential genome-wide G × E interactions between body mass index (BMI) and common SNPs for colorectal cancer risk using data from 36,415 colorectal cancer cases and 48,451 controls from three international colorectal cancer consortia (CCFR, CORECT, and GECCO). The G × E tests included the conventional logistic regression using multiplicative terms (one degree of freedom, 1DF test), the two-step EDGE method, and the joint 3DF test, each of which is powerful for detecting G × E interactions under specific conditions. BMI was associated with higher colorectal cancer risk. The two-step approach revealed a statistically significant G×BMI interaction located within the Formin 1/Gremlin 1 (FMN1/GREM1) gene region (rs58349661). This SNP was also identified by the 3DF test, with a suggestive statistical significance in the 1DF test. Among participants with the CC genotype of rs58349661, overweight and obesity categories were associated with higher colorectal cancer risk, whereas null associations were observed across BMI categories in those with the TT genotype. Using data from three large international consortia, this study discovered a locus in the FMN1/GREM1 gene region that interacts with BMI on the association with colorectal cancer risk. Further studies should examine the potential mechanisms through which this locus modifies the etiologic link between obesity and colorectal cancer. Significance: This gene-environment interaction analysis revealed a genetic locus in FMN1/GREM1 that interacts with body mass index in colorectal cancer risk, suggesting potential implications for precision prevention strategies.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Haley, Connie A. , Ashkin, David , Peloquin, Charles A. , Cegielski, J. Peter , Andrino, Barbara B, Burgos, Marcos, Caloia, Lori A, Chen, Lisa , Colón‐Semidey, Angel, DeSilva, Malini B. , Dhanireddy, Shireesha , Dorman, Susan E. , Dworkin, Felicia , Hammond-Epstein, Heidi, Easton, Alice V. , Gaensbauer, James , Ghassemieh, Bijan J., Gómez, María Elena, Horné, David , Jasuja, Supriya , Jones, Betsy A., Kaplan, Leonard J., Khan, Asharaf Edward, Kracen, Elizabeth, Labuda, Sarah M. , Landers, Karen M., Lardizabal, Alfred , Lasley, Maria T, Letzer, David, Lopes, Vinicius K, Lubelchek, Ronald , Macias, C. Patricia, Mihalyov, Aimee, Misch, Elizabeth Ann , Murray, Jason A., Nilsen, Diana , Ninneman, M.J., Ogawa, Lynne, Oladele, Alawode, Overman, Melissa C, Ritger, Kathleen A., Rowlinson, Marie‐Claire , Sabuwala, Nadya, Schiller, Thomas M, Schwartz, Lawrence E., Spitters, Christopher, Thomson, Douglas B, Tresgallo, Rene Rico, Valois, Patrick , Goswami, Neela D. , Group, for the BPaL Implementation, Agraz-Lara, Rocio, Ahmed, Amina , Alvarez, Ana , Armitage, Lisa, Belknap, Robert , Bravo, Mary, Brode, Sarah K. , Burden, Elizabeth, Burzynski, Joseph , Caplan‐Shaw, Caralee , Castro, Ken, Chorba, Terry, Cook, Victoria , Cruz, Andrea T. , Dasgupta, Shom, Dhingra, Sonia, Elmore, Ellen, Erwin, Frank, Escuyer, Vincent, Fiske, Christina T. , Gadkowski, Beth, Henestroza, Germán, Higashi, Julie, Keh, Chris , Khalil, Amanda , Kigonya, Lilian, Lauzardo, Michael , Morris, Sapna Bamrah , Nabity, Scott A. , Oxtoby, Margaret J., Patrawalla, Amee , Raftery, Ann, Reed, Caitlin , Rock, Brian, Russo, Kelly, Sahini, Harleen, Saleeb, Paul , Santos, Roberto P. , Seaworth, Barbara , Shaw-Kaikai, Joanna, Starke, J R, Stout, Jason E. , Stubblefield, Wesley, Temesgen, Zelalem , Thomas, Keziah, Urbine, Daniel , Warkentin, Jon, Webb, Risa M. , Wortham, Johnathan, Yu, and Salinia, Altman, C, Hafiz, Irfan, Prabhakar, Deepa, Bowler, William, Gaensbauer, James T , Peloquin, Charles A , Schechter, Marcos C , Narita, Masahiro , Ray, Susan M , Group, for the BPaL Implementation, Alvarez, Ana, Armitage, Lisa, Barry, Pennan M. , Bernardo, John , Connors, William J. A. , Daley, Charles L. , Dobbs, Thomas E. , Escuyer, Vincent , Katrak, Shereen S. , Munsiff, Sonal S. , Phillips, Allison, Stubblefield, Wes, Thomas, Keziah, Tornheim, Jeffrey A. , Upton, Caryn M. , Wang, Shuhua , Wilson, John , Altman, Claudia

Mayo Clinic

Clinical Infectious Diseases | May 30, 2023 | Volume: 77 | Issue: 7 | Pages: 1053-1062

10.1093/cid/ciad312 | PMID 37249079 Get It

Abstract Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
The clot thickens: How to use viscoelastic testing in critical illness
Rech, Megan A. , Nei, Scott D. , Brown, Caitlin S. , Rech, Megan A , Gilbert, Brian W. , Garg, Ravi

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 27, 2023 | Volume: 6 | Issue: 8 | Pages: 954-963

10.1002/jac5.1829 Get It

AbstractCoagulopathy is common in critically ill patients and may result in complications such as bleeding or thromboembolic events. Viscoelastic testing (VET), including both thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®), offers a benefit over conventional coagulation tests in that it provides a qualitative and quantitative assessment of the degree of coagulopathy, including the ability to measure fibrinolysis. This review is a “how‐to” primer for critical care pharmacists to interpret and utilize VET in practice across a spectrum of coagulopathies, including trauma and traumatic brain injury, neurologic injury and emergencies, cardiothoracic surgery, liver disease, and medication‐induced coagulopathy.
Rare variants in ANO1 , encoding a calcium-activated chloride channel, predispose to moyamoya disease
Pinard, Amélie , Ye, Wenlei , Fraser, Stuart , Rosenfeld, Jill A. , Pichurin, Pavel N. , Hickey, Scott E. , Guo, Dongchuan , Cecchi, Alana C. , Boerio, Maura L. , Guey, Stéphanie , Aloui, Chaker , Alyemni, Saleh, Bamshad, Michael J. , Nickerson, Deborah A. , Jin, Sheng Chih , Smith, Edward R. , Haider, Shozeb , Jin, Sheng Chih , Milewicz, Dianna M , Rosenfield, Jill A , Guey, Stéphanie , Smith, Edward , Lee, Kwanghyuk , Kraemer, Markus , Tournier‐Lasserve, Elisabeth , Haider, Shozeb , Kahle, Kristopher T. , Jan, Lily Yeh , He, Mu , Milewicz, Dianna M.

Mayo Clinic

Brain | May 24, 2023 | Volume: 146 | Issue: 9 | Pages: 3616-3623

10.1093/brain/awad172 | PMID 37253099 Get It

Abstract Moyamoya disease, a cerebrovascular disease leading to strokes in children and young adults, is characterized by progressive occlusion of the distal internal carotid arteries and the formation of collateral vessels. Altered genes play a prominent role in the aetiology of moyamoya disease, but a causative gene is not identified in the majority of cases. Exome sequencing data from 151 individuals from 84 unsolved families were analysed to identify further genes for moyamoya disease, then candidate genes assessed in additional cases (150 probands). Two families had the same rare variant in ANO1, which encodes a calcium-activated chloride channel, anoctamin-1. Haplotype analyses found the families were related, and ANO1 p.Met658Val segregated with moyamoya disease in the family with an LOD score of 3.3. Six additional ANO1 rare variants were identified in moyamoya disease families. The ANO1 rare variants were assessed using patch-clamp recordings, and the majority of variants, including ANO1 p.Met658Val, displayed increased sensitivity to intracellular Ca2+. Patients harbouring these gain-of-function ANO1 variants had classic features of moyamoya disease, but also had aneurysm, stenosis and/or occlusion in the posterior circulation. Our studies support that ANO1 gain-of-function pathogenic variants predispose to moyamoya disease and are associated with unique involvement of the posterior circulation.
(159) The Discontinue Rate with Collagenase Clostridium Histolyticum for Peyronie’s Disease in a High-Volume Practice is Unexpectedly High: Identifying Opportunities for Patient Care Improvement
Lehner, K., Byrne, Edward , Rochandel, M R, Alom, Mulham , Köhler, Tobias , Ziegelmann, M, Lehner, K, Byrne, E, Helo, Sevann , Ziegelmann, M

Mayo Clinic

The Journal of Sexual Medicine | May 22, 2023 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdad060.154 Get It

Abstract Introduction Collagenase Clostridium Histolyticum (CCH) is an FDA-approved treatment for Peyronie’s Disease (PD). Based on phase-3 trials, the recommended treatment course consists of 8-injections over the course of roughly 18-20 weeks. While its efficacy has been established, less is known about patient-specific reasons for electing to discontinue CCH injection therapy. Objective To evaluate patient-reported factors associated with premature CCH discontinuation. Methods We queried a database of all patients (n=406) who underwent CCH at a single institution from 2014-2021. Patients who did not complete the recommended 8 injections were identified, and a detailed review was undertaken to determine causes of discontinuation. Patients were excluded from our analysis for the following reasons: deceased at the time of chart review, declined to participate, or could not be reached in 3 phone calls. Results Out of 406 patients who underwent Xiaflex treatment at our single institution, 133 did not complete 8 injections (32.8%). The mean number of CCH injections was 4.42 (SD 1.65). The most common reasons for discontinuing Xiaflex were satisfactory curve reduction (27%), unsatisfactory curve reduction (21%), bothersome side effect (15%), and decision to pursue surgery (12%) [Figure 1]. Other less common reasons included other health concerns, pausing treatments due to the Covid-19 pandemic, high treatment cost, transferring care elsewhere, and lack of awareness that more injections were indicated. Conclusions In our single institution study, we find that nearly 1/3 of patients who begin Xiaflex injections will not complete the full recommended treatment course. Understanding the reasons for discontinuation can help providers better stratify patients for Xiaflex treatment versus other modalities. In addition, given previous studies that indicate that 2/3 of men who fail to achieve a 20% curve reduction after their first 4 injections will go on to achieve this curve reduction after their final 4 injections, our data points to the potential impact of improved patient education for the 21% of individuals who discontinue due to unsatisfactory curve reduction (Alom et al 2021). Disclosure No